Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
- JCR, Teijin Launch Japan PI/PII of Regenerative Medicine Product for Cerebral Infarction
February 7, 2019
- Kyowa Kirin to Delay 100 Billion Yen Profit Goal, Plans 1st Voluntary Redundancy Program
February 6, 2019
- Kyowa Kirin Sales Slip 1.9% in 2018, but Profit Up on One-Off Factors
February 6, 2019
- Kyowa Kirin to Market Hisamitsu’s Transdermal Parkinson’s Drug
February 6, 2019
- Taiho Licenses Novel EGFR-TKI to US Firm Outside Japan
February 6, 2019
- Q3 Earnings Rundown: Eisai, Takeda, Ono, and More
February 5, 2019
- Ichiro Watanabe to Head Up Teijin Pharma
February 5, 2019
- Oropharyngeal Candidiasis Drug Oravi Now Available in Japan
February 4, 2019
- Takeda Drops US Filing for Ninlaro Label Expansion, Plans Resubmission with OS Data
February 4, 2019
- Keytruda Beats Opdivo in Q4 Global Sales including Asia
February 4, 2019
- Sawai and 7 Other Generic Makers Seeking Lyrica Patent Invalidity
February 4, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
February 1, 2019
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
- Daiichi Sankyo Selling Takatsuki Plant to Taiyo for 37.6 Billion Yen
February 1, 2019
- Ono Grabs Asian Rights to Repare’s Pol-theta Inhibitor
February 1, 2019
- JT Files Topical JAK Inhibitor in Japan for Atopic Dermatitis
February 1, 2019
- FDA Nixes Sunovion’s Parkinson’s Drug, but Requires No New Studies
February 1, 2019
- Fycompa Filed for Monotherapy, Pediatric Use in Japan: Eisai
January 31, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…